VeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14

Press/Media: Press / Media

PeriodJun 11 2016

Media coverage

12

Media coverage

  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletBloomberg
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletPR Newswire
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletPR Newswire
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletIndividual.com
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletWorldNetDaily
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletBioSpace
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletYahoo! Finance
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletYahoo! Singapore
    CountrySingapore
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletTickerTech.com
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletDaily Times Leader
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outlet9&10 News
    CountryUnited States
    Date6/11/16
    PersonsRalph A Defronzo
  • TitleVeroScience Continues to Explore Clinical Benefits of Circadian Neuroendocrine Resetting Therapy® with Six Papers Presented at 2016 American Diabetes Association Scientific Sessions June 10-14
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date6/11/16
    PersonsRalph A Defronzo